Glumetza Patent Settlement Without An Authorized Generic Plus Price Hike Spawns Litigation

 
• By Brenda Sandburg

Walgreen and other retailers allege no-authorized generic patent settlement for extended-release metformin allowed Santarus (Valeant) to block generic entry for four years while raising the price more than 750%.

Metformin prescription bottle with tablets and lid. - Image
Walgreen and other direct purchasers and end payers allege Glumetza patent litigation settlement led to Valeant price hike

More from Legal & IP

More from Pink Sheet